Navigation Links
EpiVax Reports $5.2 Million for New Q Fever Vaccine Means There is Hope for Vaccines On Demand

PROVIDENCE, R.I., June 11, 2015 /PRNewswire/ -- EpiVax reports today that the Defense Threat Reduction Agency (DTRA) is investing $5.2 Million for the development of a new type of vaccine against Q fever. Academic and industry organizations from around the world, led by Mark Poznansky of the Vaccine and Immunotherapy Center (VIC) and Massachusetts General Hospital and Annie De Groot of EpiVax (Providence, Rhode Island) have joined forces to focus on rapid vaccine development for emerging infectious disease. The VaxCelerate consortium includes collaborators from Colorado State University in Fort Collins; InnatOss Laboratories in Oss, the Netherlands and Yale University in New Haven, Connecticut.

EpiVax contributes first-in-class immunoinformatics tools to speed the pace of vaccine development and provide rapid clues about the likelihood of success in human trials. "EpiVax has worked hard to be at the forefront of the 'vaccines on demand' concept.  Their selection as a partner in this project recognizes their leadership in terms of developing safer, more efficient vaccines and improving our national biodefense rapid response capabilities," stated U.S. Senator Jack Reed (D-RI), the Ranking Member of the Armed Services Committee.

Following a delayed response to the H1N1 flu in 2009, the U.S. federal government has made major investments in rapid vaccine manufacturing approaches. The VaxCelerate effort received early funding from the Defense Advanced Research Programs Agency (DARPA) to integrate cutting-edge technologies into an end-to-end vaccine development process. The consortium was able to successfully develop and test a new vaccine for Lassa fever in 120 days, starting only from genomic data on the virus. The current DTRA-funded project focuses on the development of an RNA-based vaccine that will promote protective responses against the Q fever bacteria without the potential safety issues that prevent existing vaccine candidates from receiving US regulatory approval for use in humans.

About EpiVax
EpiVax is a biotechnology company based in Providence, Rhode Island with expertise in immunology, immunoinformatics, immunogenicity screening, deimmunization, and immune modulation. EpiVax leverages computational tools to engineer safer, more effective therapeutic proteins and rapidly design protective and efficacious new vaccines.

About Q Fever
Q fever is a worldwide disease caused by the bacteria Coxiella burnetii. Humans are susceptible to the disease, and few organisms may be required to cause infection.

Steven Vessella

Logo -

Copyright©2015 PR Newswire.
All rights reserved

Related medicine technology :

1. Xencor Reports Complete Data Results on XmAb5871 Program at European League Against Rheumatism (EULAR) 2015 Annual Meeting
2. Cantel Medical Reports Results For The Third Quarter Ended April 30, 2015
3. VirtualScopics, Inc. Reports Voting Results At Annual Meeting Of Shareholders; All Board Seats Renewed
4. Cyberonics Reports Quarter And Annual Results
5. U.S. Pet Medications Market to Reach $10 Billion by 2018, Remains Hotbed for Intense Competition, finds Reports by Packaged Facts and the FTC
6. MGC Diagnostics Corporation Reports Fiscal 2015 Second Quarter Results
7. Global Sanitation Fund Reports Major Sanitation & Hygiene Advances for Seven Million People in 13 Countries
8. Third Quarter results - Fiscal 2015 - Ergoresearch reports its results for the quarter ended March 31, 2015
9. BioLight Reports First Quarter 2015 Financial Results
10. TV Mesh Lawsuit Funding Firm, Fair Rate Funding, Reports Delaware Woman Awarded $100 Million Against Boston Scientific in Pelvic Mesh Verdict.
11. Essa Pharma Inc. Reports Second Quarter 2015 Financial Results
Post Your Comments:
(Date:9/18/2017)... Sept. 18, 2017 EpiVax, Inc. ... bioinformatics and immune engineering, today announced a ... A (H7N9) vaccine. ... seasonal influenza and presents a challenge for ... exposure to be effective. Using state-of-the-art bioinformatics and ...
(Date:9/12/2017)... NEW YORK , Sept. 12, 2017   EcoVadis , ... supply chains, has published the first annual edition of its Global CSR ... than 20,400 companies evaluated by EcoVadis, based on Scorecard Ratings that analyzed ... ... & Performance Index ...
(Date:9/12/2017)... Sept. 12, 2017  ValGenesis Inc., the global ... is pleased to announce the appointment of Dr. ... its Board of Directors and Chairman of Advisory ... life science companies to manage their entire validation ... paper in this process. Furthermore, ValGenesis VLMS enables ...
Breaking Medicine Technology:
(Date:10/13/2017)... CT (PRWEB) , ... October 13, 2017 , ... ... long-term care services, staged a mock evacuation of the facility as part of a ... Shelton Fire Department, Echo Hose EMS and Shelton City Emergency Manager, as well as ...
(Date:10/13/2017)... , ... October 13, 2017 , ... Global Healthcare Management’s ... Alexandria Park in Milford, NJ. This free event, sponsored by Global Healthcare Management’s ... The fun run is geared towards children of all ages; it is a ...
(Date:10/13/2017)... ... October 13, 2017 , ... “The Journey: From the Mountains to ... to save lost souls in the Philippines. “The Journey: From the Mountains to the ... teacher of the Bible. She has taught all ages and currently teaches a class ...
(Date:10/12/2017)... ... October 12, 2017 , ... Planet Fitness, one of the largest and ... plans to open a flagship location in Covington, LA at 401 N. U.S. Highway ... store next to Office Depot in the Holiday Square shopping center. Its location allows ...
(Date:10/12/2017)... ... October 12, 2017 , ... Asante, a nationally recognized ... have expanded their existing home health joint venture through an agreement, effective October ... a joint venture home health company with Asante, delivering clinically integrated care, for ...
Breaking Medicine News(10 mins):